Skip to main content
Signal8

Jaguar Health Compliant with Nasdaq Bid Price Rule

$JAGXPress releaseMay 27, 2026, 9:00 AM ETRead the release

Jaguar Health received formal notice from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2), the Bid Price Rule, removing the threat of delisting. CEO Lisa Conte highlighted that Q1 2026 net revenue surged 816% year-over-year and 527% quarter-over-quarter, driven by a US out-license agreement with Future Pak for Mytesi and Canalevia-CA1.

Key figures

Revenue
0
Revenue Yoy
816%
Q1 revenue qoq growth
527%

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.